Amplification of the HER2 gene (ErbB2) and corresponding overexpression of the HER2 receptor occurs in approximately 20–25% of breast tumors and is associated with a worse prognosis, shorter disease-free, and overall survival in breast cancer [31]. The gene discussed is ERBB2; the disease is breast carcinoma.